Five years ago, 28 top cancer research institutes and organisations, including ECPC, came together in a unique EU-financed collaboration as the ‘EurocanPlatform’ to share infrastructure and work together on projects.
Predicted to increase significantly globally as the population ages, cancer places a substantial burden on healthcare systems particularly regarding surveillance and recurrent treatment. “We’re faced with this growing cancer burden and at the same time we’re confronted with the spiralling costs of cancer treatment and care”, says Christopher Wild, Director of the International Agency for Research on Cancer (IARC). There is now an urgent need to meet these challenges by developing long-term strategies to speed up the translation of basic discoveries into clinical and preventive applications.
European Commissioner for Research, Innovation and Science, Carlos Moedas, stated at the project’s final Annual Meeting in Brussels on November 3rd 2015 that patients should be at the centre of research. Moving to personalised medicine will lead to challenges requiring a link to digital technology and new legal and ethical standards to support international collaborations and compilation of data will be required. There is a need for cancer care that is innovative and cost-effective, and the cancer community needs to give advice and support.
Now in its final months, the EurocanPlatform project has produced some important outcomes that are hoped to impact cancer patient outcomes and reduced mortality.
Cancer Core Europe (CCE), a recently established long-term initiative between six leading cancer centres from the EurocanPlatform (Institute Gustave Roussy in Paris, Cambridge Cancer Centre, Netherlands Cancer Institute in Amsterdam, Karolinska Institutet in Stockholm, Vall D’Hebron Institute of Cancer in Barcelona and the German Cancer Research Centre (DKFZ) in Heidelberg).
This aims to create a single virtual ‘e-hospital’ which will provide powerful translational platforms, inter-compatible clinical molecular profiling laboratories with a robust underlying computational biology pipeline, standardised imaging as well as early clinical trial structures to address personalised cancer medicine. Each centre has invested funds towards this important goal.
Spearheaded by Professor Alexander Eggermont and Professor Otmar Wiestler, CCE has its roots running through the project and all the way back to 2002, when Commissioner Philippe Busquin promoted the creation of the European Cancer Research Area, saying “Europe was not delivering the outcomes expected by healthcare professionals and citizens, and there was a need to create a joint European strategy for cancer research.” EurocanPlatform’s Scientific Coordinator Julio Celis of the Danish Cancer Society Research Centre said: “I believe CCE represents the first organised step in this direction….hopefully, CCE will be a precursor to a virtual European Cancer Institute.”
Commissioner Carlos Moedas said “As I see it, digital technologies and personalised medicine will provide many of the answers we need to fight cancer in the 21st century. There is a lot we can explore, with the ultimate goal of bringing the digital and the physical together to fight cancer, so that fewer citizens become patients and more patients become survivors”.
Following on from the initial success of CCE, Dr. Christopher Wild of IARC plans to create a counterpart initiative: Cancer Prevention Europe.
He said, “To really address that challenge we needed not only to focus on improving treatment which is essential, but also trying to address the prevention of the disease and its early detection, and having a more integrated approach across those different areas.”
About the EurocanPlatform: The EurocanPlatform is an EU-funded Network of Excellence linking 23 cancer research centres and five cancer organisations aiming at institutional collaborations in translational cancer research to innovate in prevention, early detection and therapeutics. The centres are sharing infrastructures and collaborating on projects to help advance cancer research and treatment.
Funding: The EurocanPlatform is funded by the European Union Seventh Framework Programme (FP7/2011-2015) under grant agreement n° 260791.
For more details on ECPC’s involvement within the EurocanPlatform please click here.